Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis
Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%. This was a multicenter, ran...
Gespeichert in:
| Veröffentlicht in: | Journal francais d'ophtalmologie 2010-04, Vol.33 (4), p.241-248 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 248 |
|---|---|
| container_issue | 4 |
| container_start_page | 241 |
| container_title | Journal francais d'ophtalmologie |
| container_volume | 33 |
| creator | Robert, P-Y Bourcier, T Meddeb-Ouertani, A Khairallah, M Zaghloul, K Amraoui, A Bhagat, Y Pop, M Cochereau, I |
| description | Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%.
This was a multicenter, randomized, investigator-masked study including 1,043 patients with purulent bacterial conjunctivitis. Patients received either azithromycin twice daily for 3 days or tobramycin, 1 drop every 2 hours for 2 days, then four times daily for 5 days. The primary variable was clinical cure at the test-of-cure (TOC) visit (D9) on the worst eye. The cure was defined as bulbar conjunctival injection and discharge scores of 0. Clinical signs were evaluated at D0, D3, and D9.
In the azithromycin group 87.8% of patients and in the tobramycin group 89.4% were clinically cured at D9. Clinical cure with azithromycin was not inferior to tobramycin at D9: discharge was absent in 96.3% of patients treated with azithromycin and 95.1% with tobramycin. Azithromycin was well tolerated.
Azithromycin 1.5% for 3 days (six drops) was as effective as tobramycin for 7 days (36 drops). Furthermore, patients on azithromycin presented earlier clinical cure on Day 3 than patients on tobramycin. Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis. |
| doi_str_mv | 10.1016/j.jfo.2010.01.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733591151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733591151</sourcerecordid><originalsourceid>FETCH-LOGICAL-p140t-425ce162665f26a0c33948bdc5261d21b68af84753b11d58299eb625cafee61a3</originalsourceid><addsrcrecordid>eNo1kD1PwzAURS0kRKvSH8CCvFRMCX527CQjqsqHVIkF5shxHHCV2MF2KoWJn05Qy_R0dc89w0PoBkgKBMT9IT20LqVkzgRSQvgFWkKes4TwMl-gdQimJlAKmnMOV2hBCaWMc75EP7u2NUqqCcsQdAi9thG7FstvEz-96ydlLIaUb7CeNG68GwI-ah_GgKOrvTwBJGUb7CxWnbGzrcPBfNjw5xlGP3Z_zlqqqL2ZO-XsYbQqmqOJJlyjy1Z2Qa_Pd4XeH3dv2-dk__r0sn3YJwNkJCYZ5UqDoELwlgpJFGNlVtSN4lRAQ6EWhWyLLOesBmh4QctS12IeyVZrAZKt0N3JO3j3NeoQq94EpbtOWu3GUOWM8RKAw0zensmx7nVTDd700k_V_9PYL7sNb0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733591151</pqid></control><display><type>article</type><title>Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Robert, P-Y ; Bourcier, T ; Meddeb-Ouertani, A ; Khairallah, M ; Zaghloul, K ; Amraoui, A ; Bhagat, Y ; Pop, M ; Cochereau, I</creator><creatorcontrib>Robert, P-Y ; Bourcier, T ; Meddeb-Ouertani, A ; Khairallah, M ; Zaghloul, K ; Amraoui, A ; Bhagat, Y ; Pop, M ; Cochereau, I</creatorcontrib><description>Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%.
This was a multicenter, randomized, investigator-masked study including 1,043 patients with purulent bacterial conjunctivitis. Patients received either azithromycin twice daily for 3 days or tobramycin, 1 drop every 2 hours for 2 days, then four times daily for 5 days. The primary variable was clinical cure at the test-of-cure (TOC) visit (D9) on the worst eye. The cure was defined as bulbar conjunctival injection and discharge scores of 0. Clinical signs were evaluated at D0, D3, and D9.
In the azithromycin group 87.8% of patients and in the tobramycin group 89.4% were clinically cured at D9. Clinical cure with azithromycin was not inferior to tobramycin at D9: discharge was absent in 96.3% of patients treated with azithromycin and 95.1% with tobramycin. Azithromycin was well tolerated.
Azithromycin 1.5% for 3 days (six drops) was as effective as tobramycin for 7 days (36 drops). Furthermore, patients on azithromycin presented earlier clinical cure on Day 3 than patients on tobramycin. Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis.</description><identifier>EISSN: 1773-0597</identifier><identifier>DOI: 10.1016/j.jfo.2010.01.005</identifier><identifier>PMID: 20223555</identifier><language>fre</language><publisher>France</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Azithromycin - administration & dosage ; Azithromycin - therapeutic use ; Child ; Child, Preschool ; Conjunctiva - drug effects ; Conjunctivitis, Bacterial - drug therapy ; Conjunctivitis, Bacterial - physiopathology ; Edema - drug therapy ; Erythema - drug therapy ; Eyelid Diseases - drug therapy ; Follow-Up Studies ; Humans ; Hyperemia - drug therapy ; Infant ; Infant, Newborn ; Middle Aged ; Ophthalmic Solutions ; Safety ; Single-Blind Method ; Suppuration - drug therapy ; Tobramycin - administration & dosage ; Tobramycin - therapeutic use ; Treatment Outcome ; Young Adult</subject><ispartof>Journal francais d'ophtalmologie, 2010-04, Vol.33 (4), p.241-248</ispartof><rights>Copyright 2010 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20223555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robert, P-Y</creatorcontrib><creatorcontrib>Bourcier, T</creatorcontrib><creatorcontrib>Meddeb-Ouertani, A</creatorcontrib><creatorcontrib>Khairallah, M</creatorcontrib><creatorcontrib>Zaghloul, K</creatorcontrib><creatorcontrib>Amraoui, A</creatorcontrib><creatorcontrib>Bhagat, Y</creatorcontrib><creatorcontrib>Pop, M</creatorcontrib><creatorcontrib>Cochereau, I</creatorcontrib><title>Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis</title><title>Journal francais d'ophtalmologie</title><addtitle>J Fr Ophtalmol</addtitle><description>Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%.
This was a multicenter, randomized, investigator-masked study including 1,043 patients with purulent bacterial conjunctivitis. Patients received either azithromycin twice daily for 3 days or tobramycin, 1 drop every 2 hours for 2 days, then four times daily for 5 days. The primary variable was clinical cure at the test-of-cure (TOC) visit (D9) on the worst eye. The cure was defined as bulbar conjunctival injection and discharge scores of 0. Clinical signs were evaluated at D0, D3, and D9.
In the azithromycin group 87.8% of patients and in the tobramycin group 89.4% were clinically cured at D9. Clinical cure with azithromycin was not inferior to tobramycin at D9: discharge was absent in 96.3% of patients treated with azithromycin and 95.1% with tobramycin. Azithromycin was well tolerated.
Azithromycin 1.5% for 3 days (six drops) was as effective as tobramycin for 7 days (36 drops). Furthermore, patients on azithromycin presented earlier clinical cure on Day 3 than patients on tobramycin. Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Azithromycin - administration & dosage</subject><subject>Azithromycin - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Conjunctiva - drug effects</subject><subject>Conjunctivitis, Bacterial - drug therapy</subject><subject>Conjunctivitis, Bacterial - physiopathology</subject><subject>Edema - drug therapy</subject><subject>Erythema - drug therapy</subject><subject>Eyelid Diseases - drug therapy</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hyperemia - drug therapy</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Middle Aged</subject><subject>Ophthalmic Solutions</subject><subject>Safety</subject><subject>Single-Blind Method</subject><subject>Suppuration - drug therapy</subject><subject>Tobramycin - administration & dosage</subject><subject>Tobramycin - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1773-0597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kD1PwzAURS0kRKvSH8CCvFRMCX527CQjqsqHVIkF5shxHHCV2MF2KoWJn05Qy_R0dc89w0PoBkgKBMT9IT20LqVkzgRSQvgFWkKes4TwMl-gdQimJlAKmnMOV2hBCaWMc75EP7u2NUqqCcsQdAi9thG7FstvEz-96ydlLIaUb7CeNG68GwI-ah_GgKOrvTwBJGUb7CxWnbGzrcPBfNjw5xlGP3Z_zlqqqL2ZO-XsYbQqmqOJJlyjy1Z2Qa_Pd4XeH3dv2-dk__r0sn3YJwNkJCYZ5UqDoELwlgpJFGNlVtSN4lRAQ6EWhWyLLOesBmh4QctS12IeyVZrAZKt0N3JO3j3NeoQq94EpbtOWu3GUOWM8RKAw0zensmx7nVTDd700k_V_9PYL7sNb0w</recordid><startdate>201004</startdate><enddate>201004</enddate><creator>Robert, P-Y</creator><creator>Bourcier, T</creator><creator>Meddeb-Ouertani, A</creator><creator>Khairallah, M</creator><creator>Zaghloul, K</creator><creator>Amraoui, A</creator><creator>Bhagat, Y</creator><creator>Pop, M</creator><creator>Cochereau, I</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201004</creationdate><title>Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis</title><author>Robert, P-Y ; Bourcier, T ; Meddeb-Ouertani, A ; Khairallah, M ; Zaghloul, K ; Amraoui, A ; Bhagat, Y ; Pop, M ; Cochereau, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p140t-425ce162665f26a0c33948bdc5261d21b68af84753b11d58299eb625cafee61a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Azithromycin - administration & dosage</topic><topic>Azithromycin - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Conjunctiva - drug effects</topic><topic>Conjunctivitis, Bacterial - drug therapy</topic><topic>Conjunctivitis, Bacterial - physiopathology</topic><topic>Edema - drug therapy</topic><topic>Erythema - drug therapy</topic><topic>Eyelid Diseases - drug therapy</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hyperemia - drug therapy</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Middle Aged</topic><topic>Ophthalmic Solutions</topic><topic>Safety</topic><topic>Single-Blind Method</topic><topic>Suppuration - drug therapy</topic><topic>Tobramycin - administration & dosage</topic><topic>Tobramycin - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robert, P-Y</creatorcontrib><creatorcontrib>Bourcier, T</creatorcontrib><creatorcontrib>Meddeb-Ouertani, A</creatorcontrib><creatorcontrib>Khairallah, M</creatorcontrib><creatorcontrib>Zaghloul, K</creatorcontrib><creatorcontrib>Amraoui, A</creatorcontrib><creatorcontrib>Bhagat, Y</creatorcontrib><creatorcontrib>Pop, M</creatorcontrib><creatorcontrib>Cochereau, I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal francais d'ophtalmologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robert, P-Y</au><au>Bourcier, T</au><au>Meddeb-Ouertani, A</au><au>Khairallah, M</au><au>Zaghloul, K</au><au>Amraoui, A</au><au>Bhagat, Y</au><au>Pop, M</au><au>Cochereau, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis</atitle><jtitle>Journal francais d'ophtalmologie</jtitle><addtitle>J Fr Ophtalmol</addtitle><date>2010-04</date><risdate>2010</risdate><volume>33</volume><issue>4</issue><spage>241</spage><epage>248</epage><pages>241-248</pages><eissn>1773-0597</eissn><abstract>Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%.
This was a multicenter, randomized, investigator-masked study including 1,043 patients with purulent bacterial conjunctivitis. Patients received either azithromycin twice daily for 3 days or tobramycin, 1 drop every 2 hours for 2 days, then four times daily for 5 days. The primary variable was clinical cure at the test-of-cure (TOC) visit (D9) on the worst eye. The cure was defined as bulbar conjunctival injection and discharge scores of 0. Clinical signs were evaluated at D0, D3, and D9.
In the azithromycin group 87.8% of patients and in the tobramycin group 89.4% were clinically cured at D9. Clinical cure with azithromycin was not inferior to tobramycin at D9: discharge was absent in 96.3% of patients treated with azithromycin and 95.1% with tobramycin. Azithromycin was well tolerated.
Azithromycin 1.5% for 3 days (six drops) was as effective as tobramycin for 7 days (36 drops). Furthermore, patients on azithromycin presented earlier clinical cure on Day 3 than patients on tobramycin. Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis.</abstract><cop>France</cop><pmid>20223555</pmid><doi>10.1016/j.jfo.2010.01.005</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1773-0597 |
| ispartof | Journal francais d'ophtalmologie, 2010-04, Vol.33 (4), p.241-248 |
| issn | 1773-0597 |
| language | fre |
| recordid | cdi_proquest_miscellaneous_733591151 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Azithromycin - administration & dosage Azithromycin - therapeutic use Child Child, Preschool Conjunctiva - drug effects Conjunctivitis, Bacterial - drug therapy Conjunctivitis, Bacterial - physiopathology Edema - drug therapy Erythema - drug therapy Eyelid Diseases - drug therapy Follow-Up Studies Humans Hyperemia - drug therapy Infant Infant, Newborn Middle Aged Ophthalmic Solutions Safety Single-Blind Method Suppuration - drug therapy Tobramycin - administration & dosage Tobramycin - therapeutic use Treatment Outcome Young Adult |
| title | Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T18%3A13%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20assessment%20of%20azithromycin%201.5%25%20eye%20drops%20versus%20tobramycin%200.3%25%20on%20clinical%20signs%20of%20purulent%20bacterial%20conjunctivitis&rft.jtitle=Journal%20francais%20d'ophtalmologie&rft.au=Robert,%20P-Y&rft.date=2010-04&rft.volume=33&rft.issue=4&rft.spage=241&rft.epage=248&rft.pages=241-248&rft.eissn=1773-0597&rft_id=info:doi/10.1016/j.jfo.2010.01.005&rft_dat=%3Cproquest_pubme%3E733591151%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733591151&rft_id=info:pmid/20223555&rfr_iscdi=true |